Prostate Cancer Coverage from Every Angle

Karim Fizazi, MD, PhD, on Darolutamide Treatment in Prostate Cancer: Helping Patients Assess Benefits vs Risks

Posted: Monday, June 10, 2019

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, talks about what he tells his patients with nonmetastatic castrate-resistant prostate cancer about balancing the benefits with the risk of darolutamide-related side effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.